|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
26 April 2013 |
|
Main ID: |
JPRN-C000000331 |
|
Date of registration:
|
21/02/2006 |
|
Primary sponsor: |
|
|
Public title:
|
The protective effects of Telmisartan on the cardiovascular system
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
2006/01/01 |
|
Target sample size:
|
100 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://www.umin.ac.jp/ctr/index.htm |
|
Study type:
|
Interventional |
|
Study design:
|
Parallel Randomized
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
|
|
Address:
|
Japan |
|
Telephone:
|
hrs-hsgw@ka2.so-net.ne.jp |
|
Email:
|
hrs-hsgw@ka2.so-net.ne.jp |
|
Affiliation:
|
|
|
|
Name:
|
Hiroshi Hasegawa
|
|
Address:
|
Japan |
|
Telephone:
|
|
|
Email:
|
hasegawa-chiba@umin.ac.jp |
|
Affiliation:
|
Chiba University Graduate School of Medicine Cardiovascular Science and Medicine |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Hypertension patient
Exclusion criteria: *Secondary hypertension
*heart failure
*diabetes mellitus
*acute myocardial infarction within 6 months
*treated with PCI within 6 months
*cerebrovascular disease within 3 months
*severe renal failure (serum creatinine>3mg/dl
*severe hepatic failure
*malignant disease
Age minimum:
30years-old
Age maximum:
70years-old
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Hypertension
|
|
Intervention(s)
|
treatment with Telmisartan
treatment with Losartan
|
|
Primary Outcome(s)
|
|
blood pressure, cardiovascular clinical event,cardiac hypertrophy, cardiac function, atherosclerosis,insulin resistance, renal function
|
|
Source(s) of Monetary Support
|
|
Ministry of Education, Science, Sports, and Culture
|
|